<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) receiving hypomethylating agents commonly develop <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This double-blind study evaluated the efficacy and safety of romiplostim, a peptibody protein that increases platelets, in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> receiving <z:chebi fb="0" ids="50131">decitabine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Patients received romiplostim 750 Î¼g (n = 15) or placebo (n = 14) and <z:chebi fb="0" ids="50131">decitabine</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Median platelet counts at the beginning of each <z:chebi fb="0" ids="50131">decitabine</z:chebi> cycle trended lower in placebo-treated than in romiplostim-treated patients </plain></SENT>
<SENT sid="4" pm="."><plain><z:mp ids='MP_0001914'>Bleeding</z:mp> events occurred in 43% of placebo-treated and 27% of romiplostim-treated patients, and platelet transfusions were administered to 57% of placebo-treated and 47% of romiplostim-treated patients </plain></SENT>
<SENT sid="5" pm="."><plain>Overall clinical therapeutic response was achieved by 21% of placebo-treated and 33% of romiplostim-treated patients </plain></SENT>
<SENT sid="6" pm="."><plain>Treatment was generally well tolerated </plain></SENT>
<SENT sid="7" pm="."><plain>Progression to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) occurred in one patient per group </plain></SENT>
<SENT sid="8" pm="."><plain>Adding romiplostim to <z:chebi fb="0" ids="50131">decitabine</z:chebi> treatment is well tolerated and may be beneficial, as indicated by trends toward higher platelet counts at the beginning of each treatment cycle and lower platelet transfusion rates and percentages of patients with <z:mp ids='MP_0001914'>bleeding</z:mp> events </plain></SENT>
</text></document>